We're building a better ClinicalTrials.gov. Check it out and tell us what you think!

Key Record Dates

ClinicalTrials.gov Identifier: NCT04300556
Brief Title: A Study to Evaluate the Safety, Tolerability, and Efficacy of MORAb-202 (Herein Referred to as Farletuzumab Ecteribulin), a Folate Receptor Alpha (FRα)-Targeting Antibody-drug Conjugate (ADC) in Participants With Selected Tumor Types

First Submitted : March 6, 2020
First Submitted that Met QC Criteria : March 6, 2020
First Posted : March 9, 2020

Last Update Submitted that Met QC Criteria : January 30, 2023
Last Update Posted : January 31, 2023